Fresenius Medical Care Corporation (NYSE:FMS)‘s stock had its “buy” rating reaffirmed by investment analysts at DZ Bank AG in a research note issued to investors on Monday.

Several other research firms have also issued reports on FMS. Nord/LB restated a “buy” rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada restated a “hold” rating and issued a $44.00 price target on shares of Fresenius Medical Care Corporation in a research report on Wednesday, July 5th. UBS AG restated a “sell” rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. Zacks Investment Research upgraded Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Tuesday, July 11th. Finally, BidaskClub lowered Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.67.

Shares of Fresenius Medical Care Corporation (NYSE:FMS) opened at 45.82 on Monday. Fresenius Medical Care Corporation has a one year low of $38.05 and a one year high of $50.22. The firm has a market cap of $28.12 billion, a price-to-earnings ratio of 20.32 and a beta of 0.47. The stock has a 50 day moving average price of $48.16 and a 200 day moving average price of $44.57.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The company had revenue of $4.47 billion during the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the prior year, the business earned $0.96 earnings per share. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, equities research analysts forecast that Fresenius Medical Care Corporation will post $3.13 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/09/dz-bank-ag-reaffirms-buy-rating-for-fresenius-medical-care-corporation-fms.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC raised its position in Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock valued at $149,000 after buying an additional 420 shares in the last quarter. Pacer Advisors Inc. acquired a new position in Fresenius Medical Care Corporation during the second quarter valued at $179,000. FFT Wealth Management LLC acquired a new position in Fresenius Medical Care Corporation during the second quarter valued at $201,000. Greenleaf Trust acquired a new position in Fresenius Medical Care Corporation during the first quarter valued at $205,000. Finally, RMB Capital Management LLC acquired a new position in Fresenius Medical Care Corporation during the first quarter valued at $220,000. Hedge funds and other institutional investors own 2.84% of the company’s stock.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.